UIH(SH:688271)2024-10-31 07:38Financial Performance - The company achieved a revenue of 6.954 billion RMB in the first three quarters of 2024, with a net profit of 671 million RMB, and a gross margin of 49.41%, an increase of 0.74 percentage points year-on-year [2][6]. - Domestic market revenue reached 5.550 billion RMB, while overseas revenue was 1.404 billion RMB, reflecting a year-on-year growth of 36.49% and an international market revenue share of 20.19%, up 6.35 percentage points [2][6]. Revenue Breakdown - Equipment revenue accounted for 5.705 billion RMB, with service revenue at 967 million RMB, showing a year-on-year growth of 27.27% and a service revenue share of 13.91%, up 3.68 percentage points [2][6]. - The company maintained a strong market position in high-end and ultra-high-end product segments, with significant growth in overseas markets [2][6]. Investment and R&D - The company invested 1.318 billion RMB in R&D and 1.385 billion RMB in sales expenses, with management expenses at 412 million RMB, laying a solid foundation for future growth [2][6]. - As of Q3 2024, the company has launched over 120 products, with 42 receiving CE certification and 47 obtaining FDA approval [3][4]. Market Expansion - The company has established a presence in over 75 countries and regions, with more than 31,000 units installed in over 13,000 medical and research institutions globally [3][4]. - The flagship uMR 670 MRI system has entered the Japanese market, marking a significant milestone for Chinese brands in MRI imaging [4][5]. Future Outlook - The company anticipates continued growth in overseas markets, particularly in North America and Europe, driven by high-end product demand and local service enhancements [7][8]. - The focus on high-end and ultra-high-end products, along with the introduction of new technologies, is expected to strengthen the company's competitive position in the global market [12][14].